Abstract
Objective: Within the last decades several clinical trials were performed to analyze the effectiveness of cisternal and ventricular lavage on cerebral vasospasm in patients suffering from subarachnoid hemorrhage. Aim of the present analysis was to review and summarize all documented clinical studies using cisternal or ventricular lavage to prevent vasospasm.
Methods: The MEDLINE Web site (www.pub.med.com) was searched using the clinical query function optimized for clinical therapy. Search terms were subarachnoid hemorrhage, vasospasm, cisternal and ventricular lavage. Results were divided into cisternal and ventricular lavage therapies alone and its combination with additional treatment modalities.
Results: So far the literature search revealed a total of nine clinical trials using cisternal or ventricular lavage alone in patients suffering from subarachnoid hemorrhage. The patients were treated using urokinase or recombinant tissue plasminogen activator. A metaanalysis, investigating a total of 652 included patients revealed a significant reduction of delayed neurological deficits, a significant increase of outcome and a significant decrease of mortality in the treatment group. Additional there was no difference of effectiveness or side effects using urokinase or recombinant tissue plasminogen activator. Hence, only one of these studies was based on a prospective, randomized study design. A combination of cisternal or ventricular lavage with some sort of kinetic treatment was documented in a total of three studies. All of them were designed prospectively. The combined application demonstrated reduced delayed neurological deficits, reduced vasospasm and better outcome in two studies for the treatment group. One study was stopped early due to unexpected complication.
Conclusions: In conclusion, there is strong evidence that cisternal or ventricular lavage alone and in combination with kinetic therapy lead to a reduction of cerebral vasospasm and better outcome in patients suffering from subarachnoid hemorrhage. As a consequence a prospective randomized study would be of great interest.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Amin-Hanjani S, Ogilvy CS, Barker FG, II. Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery 2004;54:326–34; discussion 334–325.
Aoki N. “Head-shaking syndrome” neurological deterioration during continuous head-shaking as an adjunct to cisternal irrigation for clot removal in patients with acute subarachnoid haemorrhage. Acta Neurochir (Wien). 1995;132:20–25.
Barker FG, II, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. J Neurosurg. 1996;84:405–414.
Barth M, Capelle HH, Weidauer S, Weiss C, Munch E, Thome C, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke 2007;38:330–336.
Findlay JM. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 1995;37:1026–1027.
Gorski R, Zabek M, Jarmuzek P. Influence of intraoperative using of recombinant tissue plasminogen activator on the development of cerebral angiospasm after subarachnoid haemorrhage in patients with ruptured intracranial aneurysms. Neurol Neurochir Pol. 2000;34:41–47.
Haley EC, Jr, Kassell NF, Alves WM, Weir BK, Hansen CA. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1995;82:786–790.
Haley EC, Jr, Kassell NF, Apperson-Hansen C, Maile MH, Alves WM. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg. 1997;86:467–474.
Hanggi D, Eicker S, Beseoglu K, Behr J, Turowski B, Steiger HJ. A multimodal concept in patients after severe aneurysmal subarachnoid hemorrhage: results of a controlled single centre prospective randomized multimodal phase I/II trial on cerebral vasospasm. Cen Eur Neurosurg. 2009;70:61–67.
Hanggi D, Liersch J, Turowski B, Yong M, Steiger HJ. The effect of lumboventricular lavage and simultaneous low-frequency head-motion therapy after severe subarachnoid hemorrhage: results of a single center prospective Phase II trial. J Neurosurg. 2008;108:1192–1199.
Hänggi D, Liersch J, Wöbker G, Steiger H. Simultaneous head rotation and lumboventricular lavage in patients after severe subarachnoid haemorrhage: An initial analysis of the influence on clot clearance rate and cerebral vasospasm. Acta Neurochir Suppl. 2008;104:315–319.
Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 1997;28:660–664.
Kanamura K, Waga S, Sakakura M, Morikawa A, Yamamoto Y, Marooka Y, et al. Comparative study of cisternal lavage methods for the treatment of cerebral vasospasm. In: Findlay JM, editor. Cerebral vasospasm: proceedings of the Vth international conference on cerebral vasospasm. Amsterdam: Elsevier Science Publishers; 1993. p. 471–473.
Kassell NF, Torner JC, Haley EC, Jr, Jane JA, Adams HP, Kongable GL. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. J Neurosurg. 1990;73:18–36.
Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T. Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery 2005;56:895–902; discussion 895–902.
Kawamoto S, Tsutsumi K, Yoshikawa G, Shinozaki MH, Yako K, Nagata K, et al. Effectiveness of the head-shaking method combined with cisternal irrigation with urokinase in preventing cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 2004;100:236–243.
Lanzino G, Kassell NF. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. J Neurosurg. 1999;90:1018–1024.
Lanzino G, Kassell NF, Dorsch NW, Pasqualin A, Brandt L, Schmiedek P, et al. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa. J Neurosurg. 1999;90:1011–1017.
Majchrzak H, Lech A, Kopera M, Gajos L, Dragan T, Ladzinski P. [Application of alteplase in prevention of cerebral vasospasm and its sequelae in patients after aneurysmal subarachnoid hemorrhage from ruptured cerebral aneurysm]. Neurol Neurochir Pol. 1995;29:379–387.
Mizoi K, Yoshimoto T, Takahashi A, Fujiwara S, Koshu K, Sugawara T. Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator. J Neurosurg. 1993;78:430–437.
Moriyama E, Matsumoto Y, Meguro T, Kawada S, Mandai S, Gohda Y, et al. Combined cisternal drainage and intrathecal urokinase injection therapy for prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 1995;35:732–736.
Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2005:CD000277.
Rinkel GJ, Feigin VL, Algra A, van Gijn J. Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2004:CD000483.
Saito I, Segawa H, Mishima K, Sano K. Prevention of postoperative vasospasm by cisternal irrigation with and without urokinase. In: Sano K, Takakura K, Kassell NF, Sasaki T, editors. Cerebral vasospasm: proceedings of the IVth international conference on cerebral vasospasm. Tokyo: Elsevier Science Publishers; 1990. p. 297–301.
Seifert V, Stolke D, Zimmermann M, Feldges A. Prevention of delayed ischaemic deficits after aneurysmal subarachnoid haemorrhage by intrathecal bolus injection of tissue plasminogen activator (rTPA). A prospective study. Acta Neurochir (Wien). 1994;128:137–143.
Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med. 2006;354:387–396.
Suzuki IS, Takahashi H. Effect of head-shaking method on clot removal in cisternal irrigation. Cerebral vasospasm.Tokya: University of Tokyo Press;1990. p. 314–316.
Treggiari-Venzi MM, Suter PM, Romand JA. Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: a problem of neurointensive care. Neurosurgery 2001;48:249–61; discussion 261–242.
Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg. 2003;98:978–984.
Usui M, Saito N, Hoya K, Todo T. Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone. Neurosurgery 1994;34:235–44; discussion 244–235.
Weyer GW, Nolan CP, Macdonald RL. Evidence-based cerebral vasospasm management. Neurosurg Focus. 2006;21:E8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag/Wien
About this paper
Cite this paper
Hänggi, D., Steiger, HJ. (2011). The Influence of Cisternal and Ventricular Lavage on Cerebral Vasospasm in Patients Suffering from Subarachnoid Hemorrhage: Analysis of Effectiveness. In: Feng, H., Mao, Y., Zhang, J.H. (eds) Early Brain Injury or Cerebral Vasospasm. Acta Neurochirurgica Supplements, vol 110/2. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0356-2_17
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0356-2_17
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0355-5
Online ISBN: 978-3-7091-0356-2
eBook Packages: MedicineMedicine (R0)